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Abstract
Background: Human embryos produced by in vitro fertilization (IVF) are usually cultured to day 6 after
insemination, and good quality of embryos should develop to blastocyst stage at days 5 and 6. However, some
embryos develop slowly, thus they may form blastocysts on day 7. Most IVF laboratories culture embryos to day 6
and then discard retarded embryos that do not develop to blastocyst stage. It has been reported that transfer of
day 7 blastocysts can yield pregnancy although the rates were very low. In the present study, we evaluated the
prevalence of aneuploidy in day 7 human blastocysts and also assessed embryo implantation after transfer of
normal euploid blastocysts developed on day 7.
Methods: Day 7 blastocysts were biopsied and screened for aneuploidy. Embryo implantation was assessed by
transferring of euploid blastocysts.
Results: A total of 1966 blastocysts from 367 IVF cycles were biopsied and screened for aneuploidy. It was found
that 81.5 % of the patients had days 5 and 6 blastocysts and 18.5 % (68) patients had blastocysts developed on day
7, including 15.3 % had days 5–7 blastocysts and 3.3 % had only day 7 blastocysts. A total of 151 day 7 blastocysts,
which accounted for 7.7 % of total blastocysts, were analyzed. It was found that 36.7 % of the blastocysts were
euploid and 63.3 % had abnormal chromosomes, including aneuploidy and euploid with partial chromosome
deletion. The aneuploidy rate was also maternal age dependent and was as high as 91.7 % in patients who were
≥40 years old. During the study period, transfer of day 7 euploid blastocysts in 15 patients resulted in 2 healthy live
births.
Conclusion(s): Aneuploidy rates in day 7 human blastocysts produced by IVF are very high. However, good
euploid blastocysts have potential to implant and transfer of day 7 euploid blastocysts can result in healthy live
birth. It is suggested that day 7 blastocyst culture may be necessary in patients who need aneuploidy screening.
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Background
Embryonic aneuploidy not only affects embryo develop-
ment and implantation, but also increases miscarriage
and birth defects [1–3]. The proportion of aneuploid
embryos increases in women with aging [4–10]. Even in
young patients undergoing in vitro fertilization (IVF), it
has also been found that high proportions of embryos
are aneuploid [11–14].
Preimplantation genetic screening (PGS) by DNA
microarray and/or next-generation sequencing (NGS)
has become an advanced technology in human IVF [7–
10, 12–17]. Previously it has been found that PGS can
increase clinical pregnancy and embryo implantation
rates in patients of advanced maternal ages, recurrent
miscarriage and previous spontaneous miscarriage, as
aneuploidy is the main reason for unsuccessful embryo
implantation in these populations of patients [9, 18–20].
As widespread application of PGS in human IVF clinics,
it would appear that PGS may also increase embryo im-
plantation rate in all patients undergoing IVF including
young patients and recipients who receive egg donation
[9, 10, 12, 14, 19], especially when single embryo transfer
is performed [12, 14].
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Human embryos are usually cultured up to day 6 after
insemination, and blastocysts can be formed either on
day 5 or day 6. However, slowly developed human em-
bryos are occasionally observed and blastocysts are
formed on day 7 in some patients [21–24]. Most IVF la-
boratories do not culture embryos to day 7 as day 7
blastocyst rate is low and blastocyst quality may not be
as good as day 5 or day 6 blastocysts [21–26]. However,
a few reports indicated that transfers of day 7 blastocysts
can establish acceptable pregnancies [21, 25, 26] and
suggested that embryos from some patients should be
cultured up to day 7 [21].
PGS of human embryos have been performed on day 5
and day 6 blastocysts, and it has been reported there
were not much differences between day 5 and day 6
blastocysts in terms of embryo quality and implantation
[27, 28]. However, some reports found that day 6 blasto-
cysts had lower implantation rates as compared with day
5 blastocysts [25, 29]. As far as we know, there is still no
study or report to analyze day 7 human blastocysts in
terms of aneuploidy formation and its relationship with
embryo implantation. Therefore, in the present study,
we retrospectively collected data on PGS of day 7 blasto-
cysts derived from IVF patients in our clinic during 2014
and aimed to analyze whether a day 7 blastocyst culture
is necessary for the patients who require PGS, and




Patients undergoing IVF, embryo cryopreservation and
PGS signed written consents for all laboratory and clin-
ical procedures. The data was retrospectively collected
from the medical records at the clinic during 2014 and
the study was approved by New England Institutional
Review Board (NEIRB 14–504).
Patient stimulation and egg retrieval
Patients were stimulated with a combination of Follistim
(Organo Inc, Roseland NJ, USA), Gonal-F (EMD Serono,
Rockland MA, USA), Menopur (Ferring Pharmaceuti-
cals, Parsippany NJ, USA) and/or Bravella (Ferring Phar-
maceuticals) beginning 2–3 days after the onset of
menses. The initial dose was 150–375 IU and was ad-
justed subsequently as the stimulation progressed. To
prevent an LH surge, a GnRH antagonist, Ganirelix or
Cetrorelix (Organo Inc.), was given when the leading fol-
licle was 13–14 mm or when the estradiol level was
400 pg/ml. Human chorionic gonadotropin (hCG), Ovi-
drel (Serono USA), or a GnRH agonist, leuprolide acet-
ate (Teva North America, North Wales PA, USA), was
injected to induce final oocyte maturation when at least
two dominant follicles reached a diameter of >18 mm.
Eggs were retrieved under IV sedation via transvaginal
ultrasound between 35–37 h after hCG or leuprolide
acetate administration.
Egg insemination, embryo culture and blastocyst biopsy
Matured eggs were inseminated by intracytoplasmic
sperm injection (ICSI) 5–6 h after retrieval and insemi-
nated eggs were cultured in Global medium supplemented
with 10 % serum protein substitute (SPS) after ICSI.
Fertilization was examined 16–18 h after ICSI and nor-
mally fertilized eggs (zygotes) were cultured in Global
medium supplemented with 10 % SPS at 37 °C in a hu-
midified atmosphere of 5.5 % CO2, 5 % O2 and balanced
nitrogen until day 7 after inseminations.
At day 3, a hole about 20 μm was opened in the zona
pellucida using the ZILOS-tkTM laser system (Hamilton
Thorn Bioscience Inc., MA USA). On day 5–7, embryos
for biopsy were examined with an inverted microscope,
and if the embryos developed to a full blastocyst stage
and some trophectoderm (TE) cells started to hatch
from the opening in the zona pellucida, some hatched
TE cells (5 ~ 10) were biopsied using a 20 μm polished
biopsy pipette with assisted cutting by the laser. Blasto-
cyst biopsy was performed on TE cells at days 5, 6 and 7
depending on blastocyst development. After biopsy, the
embryo proper was cultured in Global medium supple-
mented with 10 % SPS for 1–3 h before cryopreserva-
tion. The biopsied cells were washed with a washing
buffer provided by PGS laboratories, placed in tubes
with cell lysis buffer and were then frozen at −20 °C be-
fore being processed for microarray. Samples were ana-
lyzed with Illumina BluGnome 24Sure DNA microarray
following the BluGnome 24Sure V3 protocol [9].
Blastocyst vitrification, warming and embryo transfer
All blastocysts were vitrified after the blastocoele was
completely collapsed by using Irvine vitrification kit (Ir-
vine Scientific, Irvine, CA USA). Briefly, blastocysts were
equilibrated in the warmed (37 °C) equilibration solution
for 2 min and then transferred into the warmed (37 °C)
vitrification solution (both steps were performed on a
warming stage). The blastocysts were finally loaded onto
a vitrification straw within 45 s. All embryos were vitri-
fied individually and then stored in liquid nitrogen until
warming for frozen embryo transfer (FET).
For warming, blastocysts were exposed to warming so-
lution (Irvine warming kit) at 37 °C for 1 min. Blasto-
cysts were then transferred to a dilution solution (0.5 M
sucrose) for 3 min and then to a washing solution for
10 min with a solution change after 5 min at room
temperature. After completion of the warming process,
blastocysts were washed with Global medium supple-
mented with 10 % SPS and then cultured in the same
medium for 2–16 h before transfer. Blastocyst quality
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was assessed using standard assessments developed by
the Society for Assisted Reproductive Technologies [30].
Patient preparation for frozen embryo transfer
All patients for embryo transfer received estradiol orally
and transvaginally. Intramuscular administration of pro-
gesterone oil was initiated after about 14 days of estra-
diol treatment. Endometrium thickness was measured
on the day of progesterone administration. Embryo
transfer occurred on the sixth or seventh day of proges-
terone administration and progesterone was continued
until the first serum β-hCG test two weeks after transfer.
Ongoing pregnancies were supported by continued es-
tradiol and progesterone.
Pregnancy and implantation assessment
Fourteen days after embryo transfer, pregnancy was
checked by a serum β-hCG assay. When the β-hCG
was > 5 mIU/mL the patients were regarded as having a
biochemical pregnancy. Four weeks after embryo trans-
fer, when a gestational sac and a heart beat appeared
ultrasonographically, the patients were diagnosed as hav-
ing a clinical pregnancy.
Results
As shown in Fig. 1, 1966 blastocysts from 367 patients
were obtained in the present study. It was found that
81.5 % patients had day 5 and/or day 6 blastocysts and
no blastocysts were observed on day 7. Sixty-eight pa-
tients, which accounted for 18.5 % of the total patients,
had 151 blastocysts on day 7, which accounted for 7.7 %
of the total blastocysts observed in the present study.
Out of these 68 patients, 12 patients had only day 7 blas-
tocysts, which accounted for 3.3 % of the total number
of patients in the present study.
A total of 151 blastocysts at day 7 were biopsied and an-
alyzed. As a result, 1 sample did not show test results due
to poor quality or low quantity of DNA in the sample, 55
samples (36.7 %) had normal chromosomes (euploid) and
95 samples (63.3 %) had abnormal chromosomes includ-
ing aneuploidy (91 samples, 95.8 %) and chromosomal
microdeletion (4 samples, 4.2 %).
As shown in Fig. 2, aneuploid blastocyst rates were in-
creased as maternal ages were increased from 54.7 % in
the patients less than 35 years old to 91.6 % in the pa-
tients more than 40 years old.
In the present study, 56 patients had days 5–7 blasto-
cysts but only 36 patients had euploid blastocysts and
other 20 patients did not have any euploid embryos. For
these patients who had day 5 and/or day 6 euploid blas-
tocysts, day 5 and/or day 6 euploid blastocysts were
preferentially transferred. As shown in Fig. 1, 12 patients
had only day 7 blastocysts, but two patients did not
Fig. 1 Diagraph of patient population, blastocyst development and
embryo transfer (FET). Patients were grouped based on day 5/6
blastocyst, day 5–7 blastocyst and only day 7 blastocyst formation.
Aneuploidy was analyzed only in day 7 blastocysts and clinical
outcome was also analyzed based on day 7 euploid
blastocyst transfer
Fig. 2 Abnormal day 7 blastocysts formation in patients at various
maternal ages. Numbers in the top of each bar indicate the
numbers of aneuploid blastocysts vs total number of blastocysts
biopsied and screened
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have euploid blastocysts so embryo transfer was not
performed.
As summarized in Table 1, 10 patients (number 1–10)
had day 7 euploid blastocyst transfer and one patient
was pregnancy after two good blastocysts were trans-
ferred. Finally, one embryo implanted and the patient
delivered a healthy baby, while 9 patients were not preg-
nant after single embryo transfer and the quality of blas-
tocysts is listed in Table 1. Three patients (number 11–
13) were not pregnant after transfer of a day 5 or 6 eu-
ploid blastocyst, so each patient had a day 7 euploid
blastocyst transfer, but embryos did not implant in all
three patients (one patient had good embryos, but others
had fair embryos). Two patients (number 14 and 15) had
two mixed euploid blastocysts transferred. Two blasto-
cysts (one from day 5 and another from day 7) were
transferred in patient 14 and she was pregnant but was
miscarried. Patient 15 also had two blastocysts trans-
ferred (one from day 6 and another from 7) and the pa-
tient was pregnant and delivered twins. Putting together,
these data resulted in a 20 % (3/15) clinical pregnancy
rate, a 18.8 % (3/16) implantation rate a 13.3 % (2/15)
live birth rate and after transfer of day 7 euploid blasto-
cysts in the present study.
Discussion
The present study, as far as we know, is the first study
to analyze aneuploidy formation in day 7 human blasto-
cysts produced by IVF. Previously, although there are
many publications to report aneuploidy formation in hu-
man blastocysts, all reports did not include day 7 blasto-
cysts [7–13]. In the present study, we found that 63.3 %
of day 7 blastocysts were aneuploid and the aneuploidy
rate in day 7 blastocysts was also maternal age
dependent, and was as high as 91.7 % in the patients at
ages of 40 or more. We also found that 18.5 % of the pa-
tients had blastocysts at day 7 and 3.3 % of the patients
had only day 7 blastocysts, i.e. no blastocysts at days 5
and 6. Although day 7 blastocysts accounted for only
7.7 % of the total blastocysts, and only 36.7 % of the day
7 blastocysts were euploid, transfer of these euploid blas-
tocysts can successfully result in healthy live births, indi-
cating that day 7 embryo culture may be necessary for
the patients undergoing IVF, especially for those patients
who do not have days 5 and/or 6 blastocysts.
More evidences indicate that there are more high
quality of blastocysts on day 5 than day 6 or day 7, but
the implantation rates were not different if same quality
of blastocysts were transferred, irrespective of day 5 or 6
Table 1 Clinical outcome in patients who received day 7 euploid blastocyst transfer
















1 34 0 3 1 1 Good/Good No 0 0
2 33 0 2 2 1 Fair/Fair No 0 0
3 37 0 1 1 1 Good/Good No 0 0
4 39 0 2 1 1 Good/Fair No 0 0
5 29 0 3 2 2 Good/Good Yes 1 1
Good/Good
6 39 0 3 1 1 Fair/Fair No 0 0
7 39 0 1 1 1 Fair/Fair No 0 0
8 37 0 1 1 1 Fair/Fair No 0 0
9 39 0 1 1 1 Fair/Fair No 0 0
10 37 0 3 1 1 Poor/Poor No 0 0
11b 36 1 2 1 1 Good/Good No 0 0
12b 34 1 2 1 1 Fair/Fair No 0 0
13b 29 1 1 1 1 Fair/Fair No 0 0
14e 34 1 3 1 2c Goog/Good Yes 1f 0
Good/Good
15e 35 1 1 1 2d Fair/Good Yes 2d 2d
Good/Fair
aQuality of blastocyst: inner cell mass/trophectoderm
bPatients also had previous day 5 and/or day 6 euploid blastocyst transfer but embryos failed to implant
cOne was day 5 blastocyst and another was day 7 blastocyst
dOne was day 6 blastocyst and another was day 7 blastocyst
eBlastocysts from different culture days were transferred
fPatient was pregnant but was miscarried
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[27, 28]. However, if all blastocyst (various qualities)
transfers at day 5 and day 6 were considered and com-
pared, day 5 blastocysts had higher implantation rates
[25, 29], indicating that quality of fast growing blasto-
cysts is better than slow growing blastocysts. Same as
the results in a previous study that days 5–7 blastocysts
without doing PGS were transferred [21], we also found
that both days 5 and 6 blastocysts had better quality
than day 7 blastocysts (unpublished data). Because all of
these embryos are euploid, thus the quality of embryos
would be the key factor affecting the implantation.
Lower implantation from day 7 euploid blastocysts may
be mainly due to embryo quality [21]. Indeed, in the
present study, we found that the quality of blastocysts
transferred was the key factor affecting embryo implant-
ation. No implantation was obtained if blastocysts had
both fair ICM and TE. As shown in the Table 1, most
day 7 blastocysts transferred had fair quality, thus it may
be the reason that day 7 blastocysts had low implant-
ation rate in the present study. We also observed low
implantation rates when day 5/6 blastocysts with both
fair ICM and TE were transferred (unpublished data).
Although only a small portion of IVF patients had day
7 blastocysts, or had only day 7 blastocysts, transfer of
these day 7 euploid blastocysts can result in healthy
births [21–24]. Thus it may be necessary to culture em-
bryos to day 7 in all patients or in the patients who do
not have blastocysts on days 5 and/or 6, irrespective of
PGS or not. In the present study, we collected limited
data during the study period and these results, together
with previous studies without PGS [21–24], suggest that
day 7 human embryo culture is necessary. However, we
still need more data to demonstrate if fair or poor blas-
tocysts obtained on day 7 need to be transferred or to be
biopsied for PGS. These embryos may not be “strong”
enough to undergo biopsy although biopsy of day 5/6
good blastocysts did not affect embryo implantation
[31].
Clinical pregnancy rate observed in the present study
was similar to those reported previously with day 7
blastocyst transfer without PGS [21, 24, 25]. It is difficult
to compare the outcomes between studies to get the
conclusion that PGS of day 7 blastocysts can improve
embryo implantation. From the present study, we at
least can conclude that transfer of day 7 blastocysts that
have been biopsied for PGS can result in healthy live
births.
There is still concern about the implantation rate of
euploid blastocyst transfer in IVF patients. As of the data
from published results, it would appear that the overall
implantation rates were close to 50 % if euploid blasto-
cysts were transferred. The reasons that other blasto-
cysts still cannot implant after transfer are not known.
The following factors have be considered for the low
(not 100 %) implantation rates, such as embryo quality,
transfer skills, uterine lining and acceptability of em-
bryos by uterine. However, the trauma caused by biopsy
and mosaicism of blastocysts must also be considered.
Blastocyst biopsy procedure is not non-invasive and is
performed by laser assisted cutting. Isolation a few TE
cells from a blastocyst may not affect the quality of the
embryo [31]. However, this may be dependent up on the
embryo quality and cell numbers in the embryos. If a
good blastocyst is biopsied, such side effects may be
small. However, if a fair or poor blastocyst is biopsied, it
may cause trauma to the embryos, which in turn affects
subsequent embryo implantation. Further studies are ne-
cessary to investigate the implantation of fair or poor
blastocyst after biopsy. In addition, current PGS technol-
ogy does not show mosaic status in the samples, thus it
is difficult to state if a blastocyst is mosaic or not.
Blastocyst mosaic is very common in human blastocysts
[9, 11, 32], so the test result of euploid does not mean
all cells in the remaining embryos have normal chromo-
somes. As reported by Haddad et al., transfer of a eu-
ploid blastocyst may have mosaic pregnancy [33].
Clinical application of PGS in human IVF has been in-
creased recently since DNA microarray and NGS were in-
troduced to analyze all chromosomes. Almost all practices
have switched from cleavage embryo transfer to blastocyst
transfer due to PGS procedures that need blastocyst biopsy
and time-consuming DNA analysis. PGS procedures also
requires that blastocysts are cryopreserved for future FET,
especially in clinics where DNA analysis is not done in-
house. Increase pregnancy and implantation rates have
been reported after transfer of screened euploid blastocysts,
especially in the patients with advanced maternal ages [9,
10, 19, 20]. However, as indicated in the previous reports
[29, 30, 34–36], chromosomal mosaicism may cause incor-
rect embryo screening. Diploid-aneuploid mosaicism is the
most common chromosome mosaic in human embryos
[29, 37], thus some screened as abnormal embryos may
have normal ICM, while some screened as normal embryos
may have abnormal ICM [9, 32]. A few reports indicated
that transfer of aneuploid blastocysts can result in birth of
healthy babies [34–36].
According to the previous studies, high proportions of
human blastocysts had chromosomes inconsistent between
ICM and TE or among TE cells [9, 32]. These results indi-
cated that blastocysts with abnormal chromosomes in their
whole or partial TE cells may have euploid cells in their
ICM [9, 32]. Patients may lose opportunity to get pregnant
if these embryos are not transferred. As suggested by Liu et
al. [9], it may be necessary to do a second biopsy for PGS if
all embryos were diagnosed as abnormal in an IVF cycle,
especially if the patients are young. However, according to
Greco’s report [36], transfer of aneuploid embryos after
additional consents were signed by the patients may be
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practical without a second biopsy that may cause more
damages to embryos. As PGS is a cost IVF laboratory pro-
cedure, and biopsy of blastocysts is not non-invasive, its
value to all patients, especially to young patients remains
further investigation [38]. As indicated in the previous
study by analysis of day 3 biopsy and PGS [39], multiple
centers involved data analysis with large sample size may
be necessary to demonstrate the significant effectiveness of
current PGS in human IVF.
Conclusions
In conclusion, our study indicates that aneuploidy rates
are high in day 7 human blastocysts produced by IVF.
However, euploid blastocysts can be found in day 7 blas-
tocysts and transfer of these blastocysts can result in
healthy live births. Some patients may have only day 7
blastocysts, thus 7 day embryo culture is necessary for
these patients. Our results suggest that IVF practices
may extend embryo culture to day 7 in the patients who
do not have day 5 and/or day 6 blastocysts. While for
the patients who have day 5 and/or day 6 blastocysts,
day 7 culture may not be necessary after considering of
the time and cost for the embryo culture, biopsy and
genetic testing, as well as the low rates of good and eu-
ploid blastocysts. Further studies remain necessary to in-
vestigate the effectiveness of biopsy and PGS in fair and
poor blastocysts as biopsy may negatively affect embryo’s
capability to implant and blastocyst mosaic may reduce
the available embryos for transfer.
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